undamentalytics Newsletter
Sign in

Revolution Medicines, Inc. balance sheet

At the end of fiscal 2025, Revolution Medicines, Inc. had total assets of $2.35bn, total liabilities of $723m and shareholders' equity of $1.63bn. It held $384m in cash against $0 of debt: net cash of $384m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash and equivalents7017104108161696543384
Total current assets—1344545906601,8792,3282,075
Goodwill—15151515151515
Total assets—2215677388122,0622,5582,355
Accounts payable—11131421625465
Deferred revenue (current)——121240——
Total current liabilities—43476062144164290
Long-term debt———————0
Total debt00000000
Total liabilities—6893135127236293723
Shareholders' equity−108−1534756036851,8262,2651,631
Non-controlling interests and other (assets − liabilities − equity)—305——————
Net debt (negative = net cash)−70−17−104−108−161−696−543−384
Shares outstanding——67m74m90m—186m197m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Revolution Medicines, Inc.